![Normand Balthazard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Normand Balthazard
Corporate Officer/Principal presso
Origenix Technologies, Inc.
Profilo
Normand Balthazard is the founder of CryoCath Technologies, Inc., ConjuChem, Inc., Biorthex, Inc., Intellivax International, Inc., Origenix Technologies, Inc. Former positions include President & Chief Executive Officer at BioCapital Investment Advisors, Inc. from 2002 to 2005, Co-Chief Executive Officer at Prognomix, Inc., Chairman, President, Secretary & Treasurer at Contact Image Corp.
from 2004 to 2007, and Director at Savaria Corp.
from 2003 to 2010.
Posizioni attive di Normand Balthazard
| Società | Posizione | Inizio |
|---|---|---|
Origenix Technologies, Inc. | Corporate Officer/Principal | - |
Intellivax International, Inc.
 Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Develops nasal spray vaccines | Corporate Officer/Principal | - |
Precedenti posizioni note di Normand Balthazard
| Società | Posizione | Fine |
|---|---|---|
Prognomix, Inc.
 Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Amministratore Delegato | 01/10/2012 |
| SAVARIA CORPORATION | Direttore/Membro del Consiglio | 01/03/2010 |
Contact Image Corp.
 Contact Image Corp. Commercial Printing/FormsCommercial Services Provides digital and fabric printing services | Presidente | 23/03/2007 |
BioCapital Investment Advisors, Inc.
 BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Presidente | 31/12/2005 |
Biorthex, Inc.
 Biorthex, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets surgical products | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
13
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
CryoCath Technologies, Inc.
 CryoCath Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical equipment | Health Technology |
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs or pharmaceutical substances to treat Type 2 diabetes or other diagnostic substances | Health Technology |
Savaria Corp.
 Savaria Corp. Other Consumer SpecialtiesConsumer Durables Designs and manufactures elevators, lifts and wheelchair accessible vans | Consumer Durables |
Biorthex, Inc.
Biorthex, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets surgical products | Health Technology |
BioCapital Investment Advisors, Inc.
BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Finance |
Intellivax International, Inc.
Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Develops nasal spray vaccines | Health Technology |
Contact Image Corp.
Contact Image Corp. Commercial Printing/FormsCommercial Services Provides digital and fabric printing services | Commercial Services |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Health Technology |
Origenix Technologies, Inc. |
